Roche Diagnostics Steps Up Services, Eyes Laboratory Tie-up
This article was originally published in PharmAsia News
Roche Diagnostics recently disclosed that it will step up efforts to get a slice of China's RMB 850 billion healthcare reform pie. Although the company's product portfolio includes devices catering to China's small- and mid-sized hospitals and rural specialists, it enjoys no price advantage. To address this, the firm will compete by providing high-level services. In addition, Roche Diagnostics will collaborate with local independent laboratories to meet the outsourced testing needs of small hospitals that do not own clinical testing departments. The company does not discount the possibility of acquisitions or partnerships to enhance its R&D in China. (Click here for more - Chinese Language)
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.